Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 15/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19887998 | 1.00 | BCHE (0.47) | BCHEALDH1A1MAPT | |
| SCHEMBL24931231 | 0.78 | BCHE (0.48) | BCHEALDH1A1MAPT | |
| SCHEMBL16835535 | 0.78 | BCHE (0.48) | BCHEALDH1A1MAPT | |
| SCHEMBL16835534 | 0.78 | BCHE (0.48) | BCHEALDH1A1MAPT | |
| SCHEMBL7152562 | 0.76 | BCHE (0.54) | BCHEALDH1A1MAPT | |
| SCHEMBL17618218 | 0.76 | BCHE (0.47) | BCHEALDH1A1MAPT | |
| SCHEMBL7150802 | 0.76 | BCHE (0.54) | BCHEALDH1A1MAPT | |
| SCHEMBL12199932 | 0.76 | BCHE (0.54) | BCHEALDH1A1MAPT | |
| SCHEMBL16309279 | 0.76 | BCHE (0.47) | BCHEALDH1A1MAPT | |
| SCHEMBL7276665 | 0.76 | BCHE (0.54) | BCHEALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2539333-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104266-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | BCHE 3739/4885ALDH1A1 4312/4885MAPT 1227/4885 |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | BCHE 3668/4885ALDH1A1 4127/4885MAPT 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.